BMO Capital Says Biogen's (BIIB) BIIB037 Impresses in Alzheimer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/24/2026
- US stock index futures slip as high-stakes Iran, inflation tests loom
- Oil falls ahead of US announcement of new sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
Biogen (BIIB): Alzheimer's Could Add $58/Share in Value, Says Deutsche Bank
December 2, 2014 10:32 AM ESTDeutsche Bank reiterated a Buy rating on Biogen (NASDAQ: BIIB) with a price target of $430. Earlier it reported positive data for BIIB-037 in Alzheimers. It also said data was strong enough to move into phase 3. In the view of analyst Robyn Karnauskas, Alzheimers could be worth $58 per share.
"As we had highlighted before, we see FV of Alzheimers at $58/sh for BIIB at 100%. We believe the street could be assigning 25-50% probability with this... More
RBC Comments on Biogen (BIIB) Announcement to Move BIIB-037 to Phase 3 in Alzheimer's
December 2, 2014 10:02 AM ESTRBC Capital maintained an Outperform rating on Biogen (NASDAQ: BIIB) with a price target of $375. Earlier Biogen said it would move Alzheimer drug, BIIB-037, to phase 3. Analyst Michael J. Yee called news another big call option long term.
"This morning, BIIB announced a "go" decision to move BIIB-037 to Phase III in Alzheimer's disease based on promising Phase I: 1) dose and time dependent removal of amyloid plaque; 2) statistically significant improvement in cognition at 54... More
UPDATE: Biogen Idec (BIIB) Gains Following Comments at Deutsche Bank Conference
December 2, 2014 8:41 AM EST(Updated - December 2, 2014 8:50 AM EST)
Biogen Idec (NASDAQ: BIIB) gained following comments at today's Deutsche Bank conference. The webcast began at 8:10 AM... More
